MECHANISM OF ACTION
Gefitinib is a small molecule selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that provides antitumor activity. 1, 2 The EGFR is one of the main components in regulating normal cell growth. 1 Proliferation and survival of cancer cells can result from specific signal transduction pathways that are blocked by gefitinib. 2 One advantage for gefitinib is that it causes minimal damage to normal cell function, because in malignant cancer cells it can inhibit specific deregulated pathways. 2 Patients should be selected based on the presence of EGFR exon 19 deletion or substitution mutation of exon 21. 3 These mutations are commonly found in subpopulations of non-small-cell lung cancer (NSCLC) such as persons of East Asian origin, females, and nonsmokers with adenocarcinoma tumors. 4
PHARMACOKINETICS
A single 50 mg dose of geftinib has a maximum plasma concentration (C max ) of 31 ng/mL, a mean time to maximum concentration (t max ) of 3 hours, a mean area under the time versus concentration curve (AUC 0-24h ) of 378 ng•h/mL, and a terminal half life (t 1/2 ) of 38 hours. 2 A single dose of 100 mg has a C max of 43 ng/mL, a mean t max of 4 hours, a mean AUC 0-24h of 531 ng•h/mL, and a mean t 1/2 of 35 hours. 2 A 225 mg dose has a C max of 150 ng/mL, a mean t max of 4 hours, a mean AUC 0-24h of 1,986 ng•h/mL, and a mean t 1/2 of 30 hours. 2 Multiple doses of 50 mg, 100 mg, and 225 mg demonstrated a C max of 60, 105, and 341 ng/mL, respectively; a median t max range of 5 to 6 hours; a mean AUC 0-24h of 1,021 ng•h/mL to 5,191 ng•h/mL; and a mean t 1/2 of 52, 45, and 40 hours, respectively. 2 Multiple doses of 400 to 700 mg have a mean C max range of 779 ng/mL to 1,156 ng/mL, a mean t max of 3 to 5 hours, a mean AUC 0-24h range of 11,399 ng•h/mL to 21,580 ng•h/mL, and a mean t 1/2 of 45 hours to 55 hours. 2 Selected therapeutic regimens of gefitinib are listed in Table 1 .
ADMINISTRATION
A. Gefitinib is administered by mouth once daily, with or without food.
B. Patients with difficulty swallowing may submerge the tablet in 4 to 8 ounces of water and stir for approximately 15 minutes. The resulting suspension is swallowed or administered via feeding tube. The container is rinsed with 4 to 8 ounces of water and the solution is swallowed or administered via feeding tube immediately. 3
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
A. Cardiovascular: Cardiac failure (all grades) 3%, (grade 3 or 4) 2% 5 ; fluid retention (grade 1 or 2) 7% 6 ; hypertension (all grades) 8% 5 ; peripheral edema (all grades) 4%, (grade 3 or 4) 0.1% 7 ; prolongation of PR interval (grade 1) 3%. 2 B. Central Nervous System: Dizziness (all grades) 7% 8 ; headache (grade 1 or 2) 15%, (grade 3) 1%. 1 C. Constitutional: Asthenia (all grades) 13%, 6 (grade 1 or 2) 8% to 25%, 1,4-7,9 (grade 3 or 4) 3% to 10% 1, 4, 6, 7 ; fatigue (all grades) 22% 8 ; pyrexia (grade 1 or 2) 7% to 10%, (grade 3 or 4) 0.3% to 1% 6, 7 ; somnolence (grade 1 or 2) 18%, (grade 3) 3%. 1 D. Dermatologic: Acneiform rash (grade 1 or 2) 13% to 63%, 1, 2, 4, 6, 8, 9 (grade 3 or 4) 1% to 4% 1, 4, 6, [8] [9] [10] ; alopecia (all grades) 3% 2,6 ; dermatitis acneiform (all grades) 7% 5 ; dry skin (grade 1 or 2) 7% to 27% 1, [5] [6] [7] 9, 10 ; paronychia (all grades) 3%, (grade 3 or 4) 0.1% 7 ; pruritus (all grades) 8% to 31%, 7-10 (grade 3 or 4) 0.3% 7 ; rash (all grades) 37% to 45%, 5, 7 (grade 3 or 4) 2% 7 ; seborrhea (grade 1 or 2) 20%. 2 E. Eye Disorder: Corneal disease (all grades) 13%, 2 eye disorders (all grades) 6%, 2 keratitis and blepharitis (all grades) 10%. 2 F. Gastrointestinal: Anorexia (grade 1 or 2) 5% to 32%, 1,2,9,10 (grade 3 or 4) 1% to 2%, 4-6,10 (all grades) 10% 7 ; constipation (grade 1 or 2) 7% to 11%, 4-6 (grade 3 or 4) 1% 4,6 ; diarrhea (grade 1 or 2) 20% to 49%, 2,5,9 (grade 3 or 4) 4% to 9% 1,6-8,10 ; nausea (grade 1 or 2) 10% to 33%, 2,5,8-10 (grade 3 or 4) 1% to 3% 1, 6, 7, 9, 10 ; pharyngitis (grade 1 or 2) 16% 1 ; stomatitis (grade 1 or 2) 6% to 9%, 6, 7 (grade 3 or 4) 0.2% 7 ; vomiting (grade 1 or 2) 6% to 34%, 1,2,5,9 (grade 3 or 4) 1% to 3% 6,7,10 ; xerostomia (grade 1 or 2) 18%. 1 G. Hematologic: Anemia (grade 1 or 2) 4% to 5%, 6,10 (grade 3 or 4) 2% 6,10 ; febrile neutropenia (grade 1 or 2) 1%, (grade 3 or 4) 1% 6 ; neutropenia (grade 1 or 2) 5%, 6,10 (grade 3 or 4) 2% to 6%. 6, 10 H. Hepatic: Alanine aminotransferase (ALT) increased (all grades) 8%, 5 (grade 1 or 2) 10% to 11%, 2,9 (grade 3) 10%, 2 (grade 3 or 4) 1% to 2% 5, 9 ; alkaline phosphatase increased (grade 1 or 2) 10% 2 ; aspartate aminotransferase (AST) increased (all grades) 6%, 5 1, 6, 7 ; hemoptysis (all grades) 5%, (grade 3 or 4) 0.4% 7 ; interstitial lung disease (all grades) 1% 5 ; interstitial pneumonitis (all grades) 2%, (grade 3 or 4) 2%. 8 M. Treatment-Related Death: Death from any adverse event considered drug-related 1% to 5%. 6, 7 
DOSAGE MODIFICATIONS
A. Hepatic: Patients with mild hepatic impairment had a mean systemic exposure increase by 40%, patients with moderate hepatic impairment increased by 263%, and patients with severe impairment increased by 166%. Hold gefitinib for up to 14 days for any grade 2 or higher AST or ALT elevations. Discontinue gefitinib for severe hepatic impairment. 3 B. Renal: No dosage reductions are necessary for renal impairment. 1, 3, 9 Name: Sonidegib Synonyms: Erismodegib, Odomzo, LDE225
MECHANISM OF ACTION
Sonidegib displays antitumor activity by inhibiting the hedgehog signaling pathway. Specifically it selectively inhibits the positive regulator component of the hedgehog pathway known as Smoothened (SMO). 11, 12 In the postnatal period through adulthood, the hedgehog pathway is instrumental in the regulation of bone development, tissue maintenance and repair, and maintenance of some stem cell populations such as those in hair follicles. 11 A mutation in SMO leads to the activation of the ligand-independent pathway and has been shown to result in basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma. 12
PHARMACOKINETICS
Following oral administration, sonidegib has a median t max of 2 hours (range, 1-48 hours). 11 For single doses of 100 mg to 400 mg, the mean C max was 85.8 to 267 ng/mL, mean AUC 0-168h was 1,880 ng•h/mL to 7,450 ng•h/mL, and median t max was 2 to 4 hours. 11 For single doses of 800 mg to 3,000 mg, the mean C max range was 430 ng/mL to 429 ng/mL, mean AUC 0-168h range was 7,870 ng•h/mL to 11,800 ng•h/mL, and median t max range was 4 to 2 hours. 11 On day 15 following a dose of 100 mg to 400 mg once daily, the mean C max was 155 ng/mL to 558 ng/mL, mean AUC 0-24h was 2,690 ng•h/mL to 10,200 ng•h/mL, and median t max was 4 to 13 hours. 11 On day 15 following a dose of 800 mg to 3,000 mg once daily, the mean C max was 840 ng/mL to 1,670 ng/mL, mean AUC 0-24h was 12,800 ng•h/mL to 24,600 ng•h/mL, and median t max was 2 hours to 5 hours. 11 Steady state was achieved in 2 to 24 weeks of repeated dosing of sonidegib, with an effective median elimination t 1/2 estimated to be about 11 days. 11 Selected therapeutic regimens of sonidegib are listed in Table 2 .
PREPARATION
A. Sonidegib is available as a 200 mg capsule.
STABILITY
A. Sonidegib should be stored at 20°C-25°C (68°F-77°F).
B. Brief (<24 hour) exposure to temperatures down to 15°C (59°F) and up to 30°C (86°F) is acceptable. 13
ADMINISTRATION
A. Sonidegib is administered by mouth once daily. B. Sonidegib should be taken on an empty stomach, a minimum of 1 hour before or 2 hours after a meal. 13 Conforms to dosing information listed in the manufacturer's labeling.
